Amid drug price worries, earnings to test U.S. pharma, biotech shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Eli Lilly (LLY) PT Maintained at $95 at Cowen on 1Q18 Report; 'Top & Bottom Line Beat... FY18 Guidance Raised'
April 24, 2018 11:50 AM EDTCowen maintained its price target on Eli Lilly (NYSE: LLY) at $95.00 while maintaining a Outperform rating, following the company's first quarter earnings report.
Analyst Steve Scala notes an upbeat outlook on the shares, as LLY reported first quarter sales and earnings per share results above... More
Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q
April 24, 2018 8:48 AM EDTPiper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.
BIIB's anti-CD20... More
Biogen (BIIB) Tops Q1 EPS by 13c, Miss on Revenues
April 24, 2018 7:00 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $6.05, $0.13 better than the analyst estimate of $5.92. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.15 billion.
Total revenues of $3.1 billion, an 11% increase versus the prior year or a 15% increase excluding hemophilia... MoreEli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg
April 24, 2018 6:01 AM EDTEli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed... More
